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Abstract
Background. Primary central nervous system lymphoma (PCNSL) is rare and there is limited genomic and immunological information available. Incidental clinical and radiographic responses have been reported in PCNSL patients treated with immune checkpoint inhibitors.
Materials and Methods. To genetically characterize and ascertain if the majority of PCNSL patients may potentially benefit from immune checkpoint inhibitors, we profiled 48 subjects with PCNSL from 2013 to 2018 with (1)
next-generation sequencing to detect mutations, gene amplifications, and microsatellite instability (MSI); (2) RNA
sequencing to detect gene fusions; and (3) immunohistochemistry to ascertain PD-1 and PD-L1 expression. Tumor
mutational burden (TMB) was calculated using somatic nonsynonymous missense mutations.
Results. High PD-L1 expression (>5% staining) was seen in 18 patients (37.5%), and intermediate expression (1–5%
staining) was noted in 14 patients (29.2%). Sixteen patients (33.3%) lacked PD-L1 expression. PD-1 expression (>1
cell/high-power field) was seen in 12/14 tumors (85.7%), uncorrelated with PD-L1 expression. TMB of greater than
or equal to 5 mutations per megabase (mt/Mb) occurred in 41/42 tumors, with 19% (n = 8) exhibiting high TMB (≥17
mt/Mb), 71.4% (n = 30) exhibiting intermediate TMB (7–16 mt/Mb), and 9.5% (n = 4) exhibiting low TMB (≤6 mt/Mb).
No samples had MSI. Twenty-six genes showed mutations, most frequently in MYD88 (34/42, 81%), CD79B (23/42,
55%), and PIM1 (23/42, 55%). Among 7 cases tested with RNA sequencing, an ETV6-IGH fusion was found. Overall,
18/48 samples expressed high PD-L1 and 38/42 samples expressed intermediate to high TMB.
Conclusions. Based on TMB biomarker expression, over 90% of PCNSL patients may benefit from the use of immune checkpoint inhibitors.

Key Points
• Primary CNS lymphoma frequently expresses high PD-L1 and tumor mutational burden.
• Further study of checkpoint inhibitor therapy in primary CNS lymphoma is warranted.
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Importance of the Study
As knowledge of the role of targeted therapies and immunotherapies in primary CNS
malignancies continues to mature, the necessity of identifying biomarkers that can
reliably predict response to treatment is of
paramount importance. Our study represents
the largest cohort of primary CNS lymphoma
tumors that have been analyzed to date
for immune checkpoint inhibition-related

Primary central nervous system lymphoma (PCNSL) is an aggressive extranodal form of non-Hodgkin’s (eg, diffuse large
B cell) lymphoma that is restricted to the brain, eyes, spinal
cord, and surrounding cerebrospinal fluid. The incidence of
PCNSL in immunocompetent patients is relatively rare, constituting 4% of all intracranial tumors and from 4% to 6% of
all extranodal lymphomas.1 In recent years, the incidence in
the elderly has been increasing.2 Although there have been
significant advances in treatment with the use of high-dose
methotrexate and rituximab, which has improved survival
tremendously, overall survival relative to other forms of nonHodgkin’s lymphoma remains poor, and disease recurrence
is very common. Up to 50% of patients with PCNSL will relapse, and 10–15% demonstrate primary refractory disease,
indicating a significant unmet therapeutic need.3
Immunotherapy in cancer, under development for many
decades, reached a seminal moment in 2011, with the FDA
approval of ipilimumab, which targeted CTLA-4 (cytotoxic
T-lymphocyte-associated protein 4), shown to be therapeutically effective in metastatic melanoma.4 The PD-1–PD-L1
axis inhibits T-cell proliferation and antitumor immune effector activity in the latter stages of the immune response
in the tumor microenvironment.5–7 The early successes of
immune checkpoint inhibition targeting the PD-1–PD-L1
(programmed death 1 and its ligand) axes in metastatic melanoma and non-small cell lung cancer8–12 firmly established
the importance of tumor-mediated mechanisms for evading
immune response and triggered enthusiasm for the use of
immunotherapies against a multitude of other solid tumors
including lymphoid malignancies.13 Anti-PD-1 has demonstrated therapeutic effects in preclinical models of lymphoma14 and in a small cohort of patients with PCNSL.15
Currently, it is unclear whether immune checkpoint inhibition would be universally beneficial in treating patients
with PCNSL or if a companion biomarker needs to be considered in the context of large-scale clinical trials. Thus far,
there has been no prior systematic examination of predictive biomarkers for response to checkpoint inhibition
in PCNSL. Tumor and tumor-infiltrating lymphocyte (TIL)
expression of PD-L1 is recognized as one of the predictive
biomarkers for immune checkpoint inhibitor responses in
various solid tumors16–19 and for Hodgkin’s lymphoma.20
Concomitant immunogenicity, as characterized by tumor
mutational burden (TMB) and hypermutability secondary
to defective DNA mismatch repair, is also considered an
enrichment biomarker for response to immune checkpoint

biomarkers, including PD-1/PD-L1 IHC, tumor
mutational burden, and microsatellite instability as well as next-generation sequencing
to identify key pathways for potential therapeutic targeting. We find that a significant
proportion of PCNSLs appears to harbor features signifying potential responsiveness to
immune checkpoint inhibition and targeted
molecular therapy.

inhibition.21–24 In view of ongoing studies of the use of
immunomodulatory therapeutics for PCNSL, we analyzed
PCNSL patients using immunohistochemistry (IHC) and
next-generation sequencing (NGS) to ascertain the incidence of response biomarkers to immune checkpoint inhibitors and performed genetic characterization to ascertain
the potential therapeutic opportunities for targeted therapy.

Materials and Methods
Ethics Statement
Human subjects were de-identified prior to analysis,
and this research is exempt under the Code of Federal
Regulations 45 CFR 46.101(b)(4) from 45 CFR part 46 requirements. We analyzed reported results for 48 patients
from a database of PCNSL patients who underwent tumor
profiling with Caris Life Sciences (Irving, TX), a CLIAcertified laboratory, from 2013 to 2018. Specimens were
obtained from multiple research centers within the United
States and had limited clinical annotation.

Next-Generation Sequencing
NGS was performed on genomic DNA isolated from
formalin-fixed paraffin-embedded tissue using the Illumina
NextSEQ platform, a 592-gene panel (n = 36) or 45-gene
panel (n = 6) used to identify mutations and gene amplification as described (http://www.carislifesciences.com)
in which there was sufficient tissue to identify potential
therapeutic targets. Because synonymous and exonic mutations do not guide the selection of therapeutics at this
time, these were not reported. Variants were detected with
greater than 99% confidence based upon allele frequency
and amplicon coverage, with an average sequencing depth
of coverage greater than 500× and analytic sensitivity of
5% variant frequency. Variants were classified according to
the American College of Medical Genetics and Genomics
guidelines.25 Microsatellite instability (MSI) was tested by
NGS. TMB was calculated using somatic nonsynonymous
missense mutations in accordance with the TMB harmonization project (http://www.focr.org/tmb), adding
nonsynonymous, nonsense, in-frame indel, and frameshift variants after filtering out presumed germline variants
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Table 1 Characteristics of Patients With Primary Central Nervous
System Lymphoma and Their Tumor Samples
Average Age

66.9 years

Age Range

39–84 years

Specimen Site

N

Frontal lobe

11

5

6

Parietal lobe

5

1

4

Temporal lobe

3

0

3

Ventricle

2

2

0

Occipital lobe

2

2

0

Thalamus

2

1

1

Basal ganglia

3

2

1

Cerebellum

1

1

0

Corpus callosum

1

0

1

Hypothalamus

1

1

0

Female

17

9

8

Total

48

24

24

Kruskal–Wallis, Pearson correlation coefficient, and linear
regression tests for statistical significance were performed using GraphPad Prism version 9.2.1 for Windows,
GraphPad Software, San Diego, CA, www.graphpad.com.

Results
Characteristics of the Analyzed Patient Cohort
Our study analyzed 48 patients diagnosed with PCNSL,
ranging from 39 to 84 years old (mean age 66.9 years) with
an even sex distribution (Table 1). Of the 31 tumors whose
sampling sites were recorded, most were from the frontal
lobe (n = 11), followed by parietal lobe (n = 5), temporal

  

90%
80%

PD-L1 IHC (SP142, rabbit) and PD-1 IHC (MRQ-22, mouse)
expression was evaluated in tumor cells and in tumorinfiltrating immune cells as previously described.29 The
respective negative controls were the Dako FLEX rabbit
immunoglobulin fraction of serum from non-immunized
rabbits, solid phase absorbed, code IS600, and the Ventana
antibody (monoclonal, catalog number 760-2014). Low
staining intensity was defined as 0%, intermediate staining
intensity was defined as 1–4% (inclusive), and high PD-L1
staining intensity was defined as greater than or equal to
5% based on the cut point for clinical responses to immune
checkpoint inhibitors.17,30

Statistical Analysis

Male

Brain, NOS

Immunohistochemistry

  
81

70%
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55 55

50%
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10%
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7
2 2 2 2 2 2 2 2 2
2 2 2 2 2 2 2 3 2 2 5 2 2 2

MYD88 (34/42)
CD79B (23/42)
PIM1 (23/42)
CARD11 (4/42)
KMT2D (5/42)
TP53 (6/46)
CCND3 (3/42)
PTEN (3/48)
CDKN2A (2/30)
CHEK2 (3/43)
EP300 (2/42)
ARID1A (1/14)
ARID2 (1/42)
BLM (1/41)
BRCA2 (1/45)
CDKN1B (1/42)
FUBP1 (1/41)
GNA13 (1/42)
HNF1A (1/48)
KMT2C (1/31)
MUTYH (1/42)
NOTCH1 (1/48)
PRDM1 (2/42)
RET (1/48)
SDHC (1/42)
SF3B1 (1/42)
MALT1 (3/42)
AKAP (1/42)
CCND3 (1/42)
CD274 (1/42)
CDK6 (1/42)
PDCD1LG2 (1/42)
PIM1 (1/42)
SRSF3 (1/42)
TEB (1/42)
TRRAP (1/42)
ETV6: IGH (1/7)

20%

NGS

CNA

Fusion

Fig. 1 Bar chart of the total number of primary central nervous system lymphomas (PCNSLs) detected with an alteration above the total N
tested, shown in parentheses. Molecular alterations were detected by next-generation sequencing (NGS) in a total of 42 sequenced PCNSLs.
NGS: mutations in DNA; CNA: copy number amplifications in DNA; Fusion: genetic fusion detected in RNA.
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determined from the Genome Aggregation Database (release 2.1), the Single Nucleotide Polymorphism Database
human build 151, and the Caris in-house benign database.
Per tumor sample, a total of 1.4 Mb was sequenced.26 Low
TMB was defined as less than or equal to 6 mutations per
megabase (mt/Mb), intermediate TMB was defined as inclusive of 7 and 16 mt/Mb, and high TMB was defined as
greater than or equal to 17 mt/Mb based on cut points established in other malignancies.27,28

3

4
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Table 2 Protein Changes Seen for the Top 6 Most Frequently
Mutated Genes in Patients With Primary Nervous System Lymphoma
Gene
MYD88
CD79B
CARD11

KMT2D

TP53

PIM1

Protein Change

N

Total

L265P

33

34

V217F

1

Y196

21

L199P

2

E626K

2

C49Y

1

D230N

1

C189X

1

Q1557fs

1

R2687X

1

S3443fs

1

R196X

1

R209fs

1

R333fs

1

R337C
I255N

1

V218_P222del

1

E135K

9

G28D

6

M1I

6

P33S

5

G99D

4

E30K

3

K24N

3

L184F

3

23
4

4

6

the L265P and Y196 residues, respectively. Other genes,
eg, PIM1 CARD11, KMT2D, and TP53, were found to have a
variety of different mutations (Table 2). There was an association of changes in MYD88 and CD79B with frontal lobe
tumors (Supplementary Figure S1); however, this was not
statistically significant and is likely related to the minimal
neurological risks of sampling a multifocal disease in this
location.

Tumor Mutational Burden and Microsatellite
Instability
TMB was quantified via the 592-gene panel, and of the 42
samples from which we could obtain these data, 8 (19%)
samples exhibited high TMB (≥17 mt/Mb), 30 (71.4%) samples exhibited intermediate TMB (7–16 mt/Mb), and 4
(9.5%) samples exhibited low TMB (≤6 mt/Mb) (Figure 2A).
No samples exhibited high levels of MSI (Figure 2C).

Expression of PD-L1 and PD-1

49

High PD-L1 expression (>5% staining) was seen in 18 cases
(37.5%), intermediate expression (1–5% staining) was
noted in 14 cases (29.2%), and 16 cases (33.3%) showed
no PD-L1 expression (Figure 2B and C). PD-1 expression
in TILs (>1 cell/high-power field) was seen in 12/14 tumors
(85.7%), but there was no association with concomitant
PD-L1 expression (Figure 2C).

Immune Checkpoint Biomarker Association

lobe (n = 3), basal ganglia (n = 3), occipital lobe (n = 2), ventricle (n = 2), thalamus (n = 2), cerebellum (n = 1), corpus
callosum (n = 1), and hypothalamus (n = 1).

Overall, 54.8% of tumors expressed either high PD-L1 expression or high TMB. PD-L1 and TMB did not co-associate
(Figure 3). Additionally, location was not significantly associated with either high TMB (P = .576) or PD-L1 expression
(P = .0542) (Supplementary Figure S2). TMB was not significantly associated with MSI. The most common mutations
such as MYD88, CD79B, and PIM1 were usually detected
in cases that had high or intermediate TMB but not necessarily high PD-L1 expression (Figure 4). Based on the expression of either high PD-L1 expression or intermediate to
high TMB, 37.5–90% of PCNSL patients may respond to immune checkpoint inhibitors. In addition, 85.7% of patients
had positive PD-1 expression and 42.8% of patients with
positive PD-1 expression also had high PD-L1 levels.

Mutations Identified by NGS and RNA
Sequencing

Discussion

Mutations were found in 26 genes, the most frequent of
which were in MYD88 (81%, 34/42), CD79B (55%, 23/42),
and PIM1 (55%, 23/42). Other mutations were found in
CARD11 (9.5%, 4/42), KMT2D (11.9%, 5/42), TP53 (13%, 6/46),
CCND3 (7.1%, 3/42), PTEN (6.3%, 3/48), and CDKN2A (6.7%,
2/30) (Figure 1). Genetic co-amplification of PD-L1 and
PD-L2 was seen in one sample. Of the 10 samples tested
with RNA sequencing, one ETV6-IGH fusion was found.
Most mutations in MYD88 and CD79B led to changes in

The purpose of this study was to determine the frequency
of expression of immune checkpoint biomarkers and their
association with known genetic alterations in PCNSL. To
characterize the immunogenicity of PCNSL, we examined
TMB and found nearly 90% of our tested cohort to have intermediate to high TMB. Based on their expression of either
high PD-L1 or intermediate to high TMB, it appears that the
majority of PCNSL patients may respond to immune checkpoint inhibitors. Higher rates of nonsynonymous TMB have

E79D

2

P125S

2

S146R

2

S97N

3

K71N

1
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Distribution of Tumor Mutational Burden

C

Checkpoint Biomarker Expression
100%
90%
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Frequency

14.30%
33.33%

70%
60%

8

50%

6

71%

29.17%

0%
85.70%

40%
30%

4

20%

2
0

10%

80%

10

10%
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30

0%

37.50%
19%

PD-L1

TMB

Tumor Mutational Burden (mt/MB)

B
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A

High

PD-1

Intermediate

MSI
Low

Representative Immunohistochemical Staining for PD-L1 and PD-1
i

ii

iii

iv

v

vi

Fig. 2 (A) Bar chart depicting numbers of patients (y-axis) expressing specific tumor mutational burden values (x-axis). (B) Representative
immunohistochemical micrographs demonstrating low (ii), intermediate (iii), and high (iv) PD-L1 staining and high (vi) PD-1 staining in PCNSL
cases with negative controls for PD-L1 (i) and PD-1 (v), respectively. Bar = 1 mm at 20× magnification. (C) Bar chart demonstrating the frequency of
expression of immune checkpoint biomarkers in PCNSLs.
  

been associated with favorable overall response rate, clinical benefit, and progression-free survival in patients who
received anti-PD-1/PD-L1 monotherapy.7,22 The cut point at
which TMB correlates with therapeutic responses may be
lineage specific and may be as low as 6 mt/Mb.31 Based on
our results and those of other researchers, it is likely that
PCNSL patients with a high TMB—with or without concomitant high PD-L1 expression—may benefit from checkpoint
inhibition. Interestingly, systemic lymphomas have a higher
TMB32 than PCNSL, and it would be interesting to identify in
matched secondary CNS lymphomas if TMB is lower than in
the primary. As such, PCNSL may have less response to immune checkpoint inhibitors than other types of lymphoma,
but further clinical study will be necessary to refine and validate TMB cutoffs in the PCNSL patient population.
Though MSI is known to be an important mechanism
of neoantigen generation in a number of solid tumors
(eg, colorectal, endometrial, and gastric) and HIV-related
lymphomas, we did not find any evidence of MSI in our
samples.33 MSI is characteristic of a tumor phenotype

5

caused by defective DNA mismatch repair (leading to the
accumulation of somatic mutations at repetitive microsatellite sequences contained in various target genes implicated in human cancers).34 Our findings are consistent with
previous reports,28,35,36 which suggest that this mechanism
is probably not a significant driver of mutational burden or
PD-1–PD-L1 axis blockade efficacy in PCNSL.
The most common genes found to be altered in PCNSL
were MYD88, CD79B, and PIM1 consistent with prior analyses.37,38 These genes are oncogenic drivers of the NF-kB
pathway,39,40 which has been shown to be associated with
PCNSL.41 There is preclinical data that HDAC inhibitors (eg,
panobinostat) work synergistically with ibrutinib in lymphoma cases harboring MYD88 mutations, and patients
with CD79B mutations tended to respond to ibrutinib.42,43
An ongoing clinical trial of ibrutinib and nivolumab in refractory PCNSL patients at MD Anderson Cancer Center
open for accrual (NCT03770416). Notably, point mutations
in the kinase PIM1, via altered interactions with upstream
regulators as well as downstream signaling, in particular,

80

R-squared: 0.004952

20
0
0

10

20

30

Tumor Mutation Burden

Fig. 3 Scatter plot demonstrating the level of tumor mutational
burden (TMB) as determined by NGS (x-axis), relative to the level
of PD-L1 expression (y-axis) in patient samples.
  

have recently been shown to reduce the sensitivity of
the activated B-cell subtype of diffuse large B-cell lymphoma to ibrutinib.44 A potential role for PIM1 as a driver
of disease recurrence has also been described.33 CARD11,
found to be mutated in 11% of our samples, is an important scaffold protein involved in signaling that controls
antigen-induced B and T lymphocyte activation during the
adaptive immune response, and gain-of-function mutations here lead to constitutive activation of NF-kB, JNK,
and mTOR.45 KMT2D encodes a DNA methyltransferase
important for global H3K4 methylation in germinal-center
B cells, and its inactivation early in B-cell development
results in increased proliferation of germinal-center B
cells.46 According to the literature, B-cell receptor/NF-kB
signaling pathways are altered in more than 90% of
PCNSLs, highlighting this receptor’s value for targeted
therapy.39 Specific NF-kB inhibitors have been developed
but are not yet available for use in clinical trials.
Despite promising findings, our study has notable limitations. We do not have the survival statistics of the patients whose samples were analyzed, which limits the
predictive significance of our findings. A clinical trial
evaluating the prognostic significance of PD-L1 is underway
(NCT04158128) and transcript variants of high PD-1 expression were shown to confer a negative prognostic outcome.47 Second, it should be noted that patients who lack
high TMB or PD-L1 expression can still have a clinical benefit from checkpoint inhibition,8,13,48 and we did not assess
for other markers of potential response such as neoantigen
burden or T-cell receptor clonality.49–51 There are likely other
biomarkers at play that have not yet even been considered
and/or devised. Third, with an arguably greater therapeutic
need for relapsed or recurrent PCNSL, our findings do not
distinguish between newly diagnosed and recurrent or relapsed disease. This concern may be mitigated by the prior
work of McGranahan et al.,52 which supports the idea that
clonal neoantigens—that is, those that occur early on in tumorigenesis rather than later subclonal neoantigens—are

TP53

KMT2D

PIM1

1
2
3
4
5
6
7
8
9
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11
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13
14
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18
19
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21
22
23
24
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26
27
28
29
30
31
32
33
34
35
36

60
40

PD-L1

TMB

100

CD79B

  
MYD88

  

Relationship Between TMB and PD-L1 Expression

CARD11
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PD-L1 Expression

6

Fig. 4 Oncoprint demonstrating the association between biomarkers
of immune checkpoint response and specific gene mutations. TMB
high: ≥17 mt/Mb; intermediate: 16 mt/Mb ≥ TMB ≥7 mt/Mb; TMB low:
≤6 mt/Mb. PD-L1 high: staining intensity ≥5%; PD-L1 intermediate: 4%
≥ PDL1 ≥1% PD-L1; low: staining intensity = 0 (negative). High expression of TMB or PD-L1 is shown in orange and intermediate in blue.
Gene mutations, amplifications, or gene fusions are shown in red; no
alterations/wild type are in gray; blank indicates missing data.
  

more important in responsiveness to immune checkpoint
inhibition. Finally, as it has been previously shown that
the relationship among TMB, MSI, and PD-L1 varies significantly by cancer type, biomarkers such as PD-L1 and TMB,
although investigated in other solid tumors, have yet to be
thoroughly validated in the PCNSL patient population. Our
data would support the use of either anti-PD-1 or anti-PD-L1

Ou et al. Primary CNS lymphoma expresses immune response markers
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